ArticleCardiovascular drugs and therapy2026
Sennoside A Ameliorates Myocardial Fibrosis After Myocardial Infarction by Binding to KDM4B and Regulates IRX2 Expression.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeMyocardial fibrosis following myocardial infarction (MI) drives the progression of heart failure, yet effective therapeutic drugs remain unavailable. This study aimed to evaluate the anti-fibrotic effect of the natural small-molecule compound sennoside A (SA) on pathological fibrosis specifically at 28 days post-MI, and to explore its underlying molecular mechanism.
methodsMouse MI models were established and treated with SA for 28 days. To evaluate therapeutic efficacy, cardiac function was assessed by echocardiography, and myocardial fibrosis was quantified using histopathological staining. For mechanistic investigation, molecular docking and enzymatic activity assays were performed to determine whether SA targets the histone demethylase KDM4B. In vitro experiments were conducted to characterize the effects of SA on fibroblast activation and extracellular matrix production.
resultsSA significantly improved cardiac function, as reflected by increased left ventricular ejection fraction (LVEF) and fractional shortening (FS). Histological analysis showed that SA significantly reduced fibrotic area and collagen deposition compared with untreated MI mice. Mechanistically, molecular docking predicted a stable interaction between SA and KDM4B, and enzymatic assays confirmed that SA inhibited KDM4B activity and increased the modification of H3K9me3. Meanwhile, IRX2 expression was significantly downregulated, which was accompanied by reduced expression of fibrotic markers, extracellular matrix deposition and fibroblast phenotypic transformation.
conclusionThis study identifies sennoside A binds to KDM4B and reduces the demethylase activity, thereby reducing IRX2 expression in a KDM4B-associated manner and ameliorating cardiac fibrosis after myocardial infarction and improving cardiac function.
Indexed as
Identifiers
42412153What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.